New hope for rare kidney disease: phase 3 trial of DMX-200 launches
Disease control
Recruiting now
This study tests an experimental drug, DMX-200, in people with a rare kidney condition called FSGS. The drug aims to reduce protein leakage in urine and slow down kidney damage. About 286 adults and teens (ages 12-80) who are already on standard blood pressure medication will rec…
Phase: PHASE3 • Sponsor: Dimerix Bioscience Pty Ltd • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC